Genfit SA

11/09/2026 | Press release | Distributed by Public on 11/09/2026 00:36

GENFIT présente les données issues des études cliniques de nangibotide soutenant la poursuite de son développement dans l’ACLF. Résultats de phase 2 attendus en 2027

Genfit SA published this content on November 09, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 09, 2026 at 06:36 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]